NLS Agreement

Agreement - June 4, 2014

AstraZeneca and Episentec in research agreement

The two companies have signed a research collaboration agreement for the development and implementation of improved methodology for early screening of potential new drug molecules. The research project will be aimed at an undisclosed drug target protein and will be utilizing the proprietary Label-Enhanced SPR biosensor technology of Episentec. Under the agreement, AstraZeneca will supply target protein and […]

Agreement - May 7, 2014

Sectra signs agreement with University Hospitals in Cleveland

The University Hospitals are to invest in dose monitoring solution from Sectra as part of large multi-year agreement. The order includes a radiation dose monitoring solution and a five-year extension of the hospital’s service and support contract for its medical IT solutions provided by Sectra. University Hospitals is one of Sectra’s largest customers in the US as […]

Agreement - April 25, 2014

Bactiguard expands in Latin America

The company has signed a distribution agreement with Promedon allowing the company to sell Bactiguard’s complete portfolio of medical devices in Argentina, Brazil, Chile and Mexico. Under the agreement, Promedon will be marketing and selling Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters in the four countries. According to Bactiguard, the company has already secured […]

Agreement - April 14, 2014

Moberg Pharma acquires treatment project

Moberg Pharma has acquired the global rights to a novel topical formulation for the treatment of oral pain. The company has announced that it has entered into a definitive agreement with Danish Oracain II Aps to acquire all assets as well as global rights to a novel and patent pending oral formulation of the proven […]

Agreement - April 4, 2014

Sobi enters partnership with Tigenix

Sobi has acquired the licencing rights to market and distribute Tigenix’s product ChondroCelect.

Agreement - April 1, 2014

Index Pharmaceuticals signs deal with Almirall

The two companies have entered into a license agreement for European rights of the phase III drug candidate Kappaproct.

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.